SOUTH SAN FRANCISCO, CALIFORNIA & NEW YORK – (COMMERCIAL THREAD) – Verily, an Alphabet company, and Colgate-Palmolive, the global leader in oral health care, today announced a strategic collaboration to advance oral health research. Under the agreement, Colgate’s dental clinical team will partner with Verily to conduct an innovative oral health study as part of Verily’s ongoing baseline health study that will aim to improve performance. understanding the links between oral health and overall human health.
The aim of the study is to see how oral health practices, including intensive non-surgical periodontal therapy, as well as a robust Colgate home oral hygiene regimen monitored through its connected technologies of intelligent toothbrush hum, affect health more widely. Periodontal treatment focuses on resolving gum and oral health problems before they become more serious and potentially lead to tooth loss.
“We are thrilled to partner with Colgate, the world’s leading oral care brand, to elucidate the impact of oral health on overall human health,” said Amy Abernethy, MD, PhD, President of Platforms of Verily’s Clinical Research Department. “This effort underscores the versatility of Verily’s benchmark platform as well as our commitment to accelerate and improve clinical research through intelligent use of data, creative collaboration and unmatched technical capabilities.
“Colgate is at the forefront of oral health research, and this innovative partnership with Verily will advance our understanding and quantify the link between improving oral health and controlling systemic conditions,” said Maria Ryan, DDS, PhD., Vice President and Chief Clinical Officer at Colgate-Palmolive. “Oral health is a window into overall health. It can provide signals of a new or worsening disease, as evidenced by the link between periodontal disease and elevated C-reactive protein, a marker of systemic inflammation, complicating diabetes control and increasing the risk of heart disease. We look forward to conducting this study with Verily and integrating the lessons to advance oral and general health care. ”
The study will recruit current participants in Verily’s ongoing core health study, aged 18 and over, with prediabetes, type 2 diabetes and / or cardiovascular disease for a period of up to 18 months. Non-surgical periodontal therapy will be administered by University of North Carolina co-investigators at Chapel Hill Adams School of Dentistry. The study “Baseline Oral Health Study: UNCoVer the Connections to General Health” has been published on clinicaltrials.gov.
“We have known for some time that oral health, cardiovascular disease and diabetes are interrelated. The depth of biological measurements in the Basic Health Study combined with the dental expertise of the UNC Adams School of Dentistry and Colgate will allow us to significantly expand our knowledge base, ”said Rob Califf, MD, head of clinical policy at Verily and Google Health. .
For more information on the study, please visit https://www.projectbaseline.com/.
About the Colgate-Palmolive Company:
Colgate-Palmolive Company is an innovative and caring growth company that is reinventing a healthier future for everyone, their pets and our planet. Focused on oral care, personal care, home care and animal nutrition, the company sells its products in more than 200 countries and territories under brands such as Colgate, Palmolive, elmex, hello, meridol, Sorriso, Tom’s of Maine, EltaMD, Filorga, Irish Spring, PCA Skin, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Soupline and Suavitel, as well as Hill’s Science Diet and Hill’s Prescription Diet. The Company is recognized for its leadership and innovation in promoting environmental sustainability and community well-being, including its achievements in saving water, reducing waste, promoting recyclability and improving children’s oral health through its Bright Smiles program, Bright Futures, which has reached over 1.3 billion children since 1991. For more information on Colgate’s global operations and how the company is building a future worthy of a smile, visit www.colgate-palmolive.com. CL-C
About Baseline de Verily
The Core Platform is an end-to-end evidence generation platform designed to accelerate scientific discovery and improve health outcomes. The core platform is designed to improve clinical trial execution, better aggregate data, and seamlessly run fully decentralized and hybrid trials. The Baseline platform also includes the Baseline community and registries, integration of wearable sensors and digital biomarkers, and drug discovery tools. In 2017, Verily launched its first initiative, the Baseline Health Study, a longitudinal observational study in partnership with Duke University School of Medicine, Stanford Medicine, Google and the American Heart Association to collect, organize and analyze large health data. phenotypic from a diverse cohort. of participants over several years. To learn more, visit verily.com/baseline.
Launched in 2015, Verily is an Alphabet subsidiary focused on life sciences and health. Verily’s mission is to make global health data useful for people to live healthier lives. Verily develops tools and devices to collect, organize and activate health data, and creates interventions to prevent and manage disease. Verily partners with leading government organizations in life sciences, medical devices and using deep expertise in hardware, software, science and healthcare to enable faster development, meaningful advancements and large-scale deployment. For more information, please visit www.verily.com.